Elanco Animal Health (NYSE:ELAN) Price Target Raised to $20.00 at Barclays

by · The Cerbat Gem

Elanco Animal Health (NYSE:ELAN – Free Report) had its price target hoisted by Barclays from $19.00 to $20.00 in a research note issued to investors on Friday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

Other equities research analysts have also issued reports about the stock. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $17.14.

Check Out Our Latest Analysis on ELAN

Elanco Animal Health Price Performance

ELAN opened at $14.27 on Friday. The company has a fifty day simple moving average of $13.90 and a 200 day simple moving average of $14.75. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92. The stock has a market cap of $7.05 billion, a P/E ratio of 35.66, a P/E/G ratio of 1.47 and a beta of 1.41. Elanco Animal Health has a 12 month low of $10.42 and a 12 month high of $18.80.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.91% and a net margin of 4.60%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the firm posted $0.18 earnings per share. Elanco Animal Health’s revenue was down 3.6% compared to the same quarter last year. On average, research analysts expect that Elanco Animal Health will post 0.92 EPS for the current year.

Insider Activity at Elanco Animal Health

In related news, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was purchased at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the purchase, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.57% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ELAN. Benjamin F. Edwards & Company Inc. lifted its stake in Elanco Animal Health by 337.7% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after purchasing an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC bought a new position in shares of Elanco Animal Health during the 3rd quarter worth approximately $29,000. ORG Partners LLC acquired a new position in shares of Elanco Animal Health during the 2nd quarter worth approximately $31,000. nVerses Capital LLC bought a new stake in Elanco Animal Health in the 2nd quarter valued at $32,000. Finally, AM Squared Ltd acquired a new stake in Elanco Animal Health during the 3rd quarter valued at $34,000. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Featured Stories